These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 14507655)
21. Involvement of apoptotic protease cascade for tissue destruction in Sjögren's syndrome. Hayashi Y; Yayagi K; Haneji N Arch Immunol Ther Exp (Warsz); 2000; 48(5):399-403. PubMed ID: 11140467 [TBL] [Abstract][Full Text] [Related]
22. Possible role of organ-specific autoantigen for Fas ligand-mediated activation-induced cell death in murine Sjögren's syndrome. Ishimaru N; Yanagi K; Ogawa K; Suda T; Saito I; Hayashi Y J Immunol; 2001 Nov; 167(10):6031-7. PubMed ID: 11698484 [TBL] [Abstract][Full Text] [Related]
23. New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model. Humphreys-Beher MG; Peck AB Arch Oral Biol; 1999 May; 44 Suppl 1():S21-5. PubMed ID: 10414851 [TBL] [Abstract][Full Text] [Related]
24. Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjögren's syndrome. Fox PC; Speight PM Crit Rev Oral Biol Med; 1996; 7(2):144-58. PubMed ID: 8875029 [TBL] [Abstract][Full Text] [Related]
25. Novel role for RbAp48 in tissue-specific, estrogen deficiency-dependent apoptosis in the exocrine glands. Ishimaru N; Arakaki R; Omotehara F; Yamada K; Mishima K; Saito I; Hayashi Y Mol Cell Biol; 2006 Apr; 26(8):2924-35. PubMed ID: 16581768 [TBL] [Abstract][Full Text] [Related]
26. Development of autoimmune arthritis with aging via bystander T cell activation in the mouse model of Sjögren's syndrome. Kobayashi M; Yasui N; Ishimaru N; Arakaki R; Hayashi Y Arthritis Rheum; 2004 Dec; 50(12):3974-84. PubMed ID: 15593201 [TBL] [Abstract][Full Text] [Related]
27. A T cell intrinsic role of Id3 in a mouse model for primary Sjogren's syndrome. Li H; Dai M; Zhuang Y Immunity; 2004 Oct; 21(4):551-60. PubMed ID: 15485632 [TBL] [Abstract][Full Text] [Related]
28. Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome. Haneji N; Nakamura T; Takio K; Yanagi K; Higashiyama H; Saito I; Noji S; Sugino H; Hayashi Y Science; 1997 Apr; 276(5312):604-7. PubMed ID: 9110981 [TBL] [Abstract][Full Text] [Related]
29. Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjögren's syndrome (SS) through up-regulated Th2 response. Saegusa K; Ishimaru N; Yanagi K; Haneji N; Nishino M; Azuma M; Saito I; Hayashi Y Clin Exp Immunol; 2000 Feb; 119(2):354-60. PubMed ID: 10632675 [TBL] [Abstract][Full Text] [Related]
30. Autoantibodies to the amino-terminal fragment of beta-fodrin expressed in glandular epithelial cells in patients with Sjögren's syndrome. Kuwana M; Okano T; Ogawa Y; Kaburaki J; Kawakami Y J Immunol; 2001 Nov; 167(9):5449-56. PubMed ID: 11673564 [TBL] [Abstract][Full Text] [Related]
31. Anti-alpha-fodrin antibodies in Sjögren's syndrome in children. Maeno N; Takei S; Imanaka H; Oda H; Yanagi K; Hayashi Y; Miyata K J Rheumatol; 2001 Apr; 28(4):860-4. PubMed ID: 11327263 [TBL] [Abstract][Full Text] [Related]
32. Antibodies against alpha-fodrin in Sjögren's syndrome. Ulbricht KU; Schmidt RE; Witte T Autoimmun Rev; 2003 Mar; 2(2):109-13. PubMed ID: 12848967 [TBL] [Abstract][Full Text] [Related]
33. Effects of free fatty acids on human salivary gland epithelial cells. Shikama Y; Ishimaru N; Kudo Y; Bando Y; Aki N; Hayashi Y; Funaki M J Dent Res; 2013 Jun; 92(6):540-6. PubMed ID: 23603335 [TBL] [Abstract][Full Text] [Related]
34. Autoantigens and Sjögren syndrome. Toda I Cornea; 2002 Mar; 21(2 Suppl 1):S13-6. PubMed ID: 11995803 [TBL] [Abstract][Full Text] [Related]
35. Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation. Bikker A; van Woerkom JM; Kruize AA; Wenting-van Wijk M; de Jager W; Bijlsma JW; Lafeber FP; van Roon JA Arthritis Rheum; 2010 Apr; 62(4):969-77. PubMed ID: 20131250 [TBL] [Abstract][Full Text] [Related]
36. Immunohistopathology of Sjögren's syndrome. Konttinen YT; Porola P; Konttinen L; Laine M; Poduval P Autoimmun Rev; 2006 Nov; 6(1):16-20. PubMed ID: 17110311 [TBL] [Abstract][Full Text] [Related]
37. Discrimination between Sjögren's and non-Sjögren's sicca syndrome by sialoscintigraphy and antibodies against alpha-fodrin and Ro/La autoantigens. Chen KS; Jiang MC; Li CJ; Liu OK; Tsai CS J Int Med Res; 2009; 37(4):1088-96. PubMed ID: 19761691 [TBL] [Abstract][Full Text] [Related]
38. Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome. Hauk V; Calafat M; Larocca L; Fraccaroli L; Grasso E; Ramhorst R; Leirós CP Clin Exp Immunol; 2011 Dec; 166(3):309-16. PubMed ID: 22059987 [TBL] [Abstract][Full Text] [Related]
39. Transfer of Sjögren's syndrome-like autoimmune lesions into SCID mice and prevention of lesions by anti-CD4 and anti-T cell receptor antibody treatment. Hayashi Y; Haneji N; Hamano H; Yanagi K Eur J Immunol; 1994 Nov; 24(11):2826-31. PubMed ID: 7957574 [TBL] [Abstract][Full Text] [Related]